浅谈替格瑞洛对治疗 ACS 患者的特点及倍林达在心内科的销售策略摘要急性冠脉综合征(ACS)具有发病率高、病情危急、致死致残率高、反复发作等特点。其发病机制为炎症介导下冠状动脉内膜不稳定性粥样斑块破裂，诱发血小板聚集，凝血酶形成，形成血栓，造成冠状动脉部分或完全阻塞，冠状动脉血流量和心肌的供需平衡被打破，心肌缺血缺氧而损伤。经皮冠状动脉介入治疗(PC7)是治疗急重 ACS 患者的主要手段，但手术过程伴随动脉机械损伤，血栓产生的风险川。因此行 PCl 治疗需要加强抗血小板和抗凝血治疗。替格瑞洛是一种新型的环戊基三唑嘧啶类受体抑制剂，能直接与受体可逆性结合，抑制血小板聚集。木文探讨替格瑞洛在 ACS 患者 PCl 术后的心脏功能，血小板凝聚功能方面的影响，为替格瑞洛的临床安全有效应用提供参考。关键词：替格瑞洛，治疗 ACS 患者，特点，倍林达，销售策略 1AbstractAcute coronary syndrome ( ACS ) has the characteristics of high incidence, critical condition, high mortality and disability rate, recurrent attacks and so on. Its pathogenesis is inflammation-mediated coronary artery intima instability atherosclerotic plaque rupture, induced platelet aggregation, thrombin formation, thrombosis, resulting in partial or complete coronary artery occlusion, coronary blood flow and myocardial supply and demand balance is broken, myocardial ischemia and hypoxia damage. Percutaneous coronary intervention ( pc7 ) is the main method to treat patients with acute and severe ACS, but the operation process is accompanied by arterial mechanical injury and the risk of thrombosis. Therefore, PCL therapy needs to strengthen antiplatelet and anticoagulant therapy. Tegrello is a novel Cyclopentyl triazolopyrimidine receptor inhibitor, which can bind directly to receptor reversibly and inhibit platelet aggregation. To investigate the effects of tegmental on cardiac function and platelet aggregation in patients with ACS after PCL, and to provide reference for clinical safe ...
